Below are the 2 most recent journal entries recorded in troilus119's InsaneJournal:

Wednesday, December 14th, 2011
3:52 am	Levofloxacin - wikipedia, the free encyclopedia ^ Nelson, JM. ; Chiller, TM. ; Powers, JH. ; Angulo, FJ. (Apr 2007). "Fluoroquinolone-resistant Campylobacter species and also the withdrawal of fluoroquinolones from easy use in poultry: a public health success story. ". Clin Infect Dis 44 (7): 97780. doi:10. 1086/512369. PMID 17342653. ^ Kawahara, S. (Dec 1998). "[Chemotherapeutic agents under study]". Nippon Rinsho 56 (12): 30969. PMID 9883617. ^ Liu, H. ; Mulholland, SG. (July 2005). "Appropriate antibiotic treatment of genitourinary infections in hospitalized patients. ". Am J Med 118 Suppl 7A (7): 14S20S. doi:10. 1016/j. amjmed. 2005. 05. 009. PMID 15993673. ^ MacDougall C, Guglielmo BJ, Maselli J, Gonzales R (March 2005). "Antimicrobial drug prescribing for pneumonia in ambulatory care". Emerging Infect. Dis. 11 (3): 3804. PMID 15757551. http://www. cdc. gov/ncidod/EID/vol11no03/04-0819. htm. ^ a b - c d e f g h i j Janssen Pharmaceutica (September 2008). "Highlights Of Prescribing Information". U. S. Food and Drug Administration (FDA). http://www. accessdata. fda. gov/drugsatfda_docs/label/2008/021721s020_020635s57_020634s52_lbl. pdf. ^ Morrissey, I. ; Hoshino, K. ; Sato, K. ; Yoshida, A. ; Hayakawa, I. ; Bures, MG. ; Shen, LL. (August 1996). "Mechanism of differential activities of ofloxacin enantiomers" (PDF). Antimicrob Agents Chemother 40 (8): 177584. PMC 163416. PMID 8843280. http://aac. asm. org/cgi/reprint/40/8/1775. pdf. ^ a b - c d DrugBank (19 February 2009). "Showing drug card for Levofloxacin (DB01137)". Canada. http://www. drugbank. ca/drugs/DB01137. ^ a b c d Renata Albrecht (19 June 2007). "NDA 20-634/S-045, NDA 20-635/S-048, NDA 21-721/S-013" (PDF). USA: U. S. Food and Drug Administration (FDA). http://www. accessdata. fda. gov/drugsatfda_docs/appletter/2007/020634s045,%20020635s048,%20021721s013ltr. pdf. ^ a b - c Renata Albrecht (16 April 2008). "NDA 20-634/S-051, NDA 20-635/S-055, NDA 21-721/S-019". U. S. Fda (FDA). http://www. accessdata. fda. gov/drugsatfda_docs/appletter/2008/020634s051,%20020635s055,%20021721s019ltr. pdf. ^ label ^ "Levofloxacin". The American Society of Health-System Pharmacists. http://www. drugs. com/monograph/levofloxacin. html. Retrieved 3 April 2011. ^ Mark J. Goldberger (17 December 1998). "Center for drug evaluation and research". U. S. Fda (FDA). http://www. accessdata. fda. gov/drugsatfda_docs/nda/98/020634s04_appltr. pdf. ^ a b - Mark J. Goldberger. "NDA 20-634/S-008, S-009, NDA 20-635/S-007, S-008". U. S. Fda standards (FDA). http://www. accessdata. fda. gov/drugsatfda_docs/appletter/2000/20635S7,8LTR. PDF. ^ Renata Albrecht,. "NDA 20-634/S-013, NDA 20-635/S-010". U. S. Fda standards (FDA). http://www. accessdata. fda. gov/drugsatfda_docs/appletter/2000/20635S10ltr. pdf. ^ Renata Albrecht. "NDA 20-634/S-025, NDA 20-635/S-022". U. S. Food and Drug Administration (FDA). http://www. accessdata. fda. gov/drugsatfda_docs/appletter/2002/20634se1-025,20635se1-022ltr. pdf. ^ Renata Albrecht (23 May 2003). "NDA 20-634/S-027, NDA 20-635/S-026". U. S. Fda standards (FDA). http://www. accessdata. fda. gov/drugsatfda_docs/appletter/2003/20634se1-027,20635se1-026ltr. pdf. ^ Nickel, JC. ; Downey, J. ; Clark, J. ; Casey, RW. ; Pommerville, PJ. ; Barkin, J. ; Steinhoff, G. ; Brock, G. et al. (October 2003). "Levofloxacin for chronic prostatitis/chronic pelvic pain syndrome that face men: a randomized placebo-controlled multicenter trial". Urology 62 (4): 6147. doi:10. 1016/S0090-4295(03)00583-1. PMID 14550427. ^ Renata Albrecht (24 November 2004). "NDA 20-634/S-035, NDA 20-635/S-035, NDA 21-721/S-003". U. S. Fda (FDA). http://www. accessdata. fda. gov/drugsatfda_docs/appletter/2004/20634s035,20635s035,21721s003ltr. pdf. ^ Renata Albrecht (8 April 2005). "NDA 20-634/S-037, NDA 20-635/S-038, NDA 21-721/S-002". U. S. Food (FDA). http://www. accessdata. fda. gov/drugsatfda_docs/appletter/2005/020634s037,020635s038,021721s002ltr. pdf. ^ a b c Renata Albrecht (23 June 2006). "NDA 20-634/S-040, NDA 20-635/S-043, NDA 21-721/S-007". U. S. Federal drug administration (FDA). http://www. accessdata. fda. gov/drugsatfda_docs/appletter/2006/020634s040,020635s043,021721s007LTR. pdf. ^ a b - Renata Albrecht (5 May 2008). "NDA 20-634/S-047, NDA 20-635/S-051, NDA 21-721/S-015". U. S. Food (FDA). http://www. accessdata. fda. gov/drugsatfda_docs/appletter/2008/020634se5-047020635se5-051021721se5-015ltr. pdf. ^ John A. Bosso (1998). "New and Emerging Quinolone Antibiotics". Journal of Infectious Disease Pharmacotherapy 2 (4): 6176. doi:10. 1300/J100v02n04_06. ISSN 1068-7777. http://bubl. ac. uk/archive/journals/jidp/v02n0498. htm#6new. ^ "SYNOPSIS" (PDF). veritasmedicine. com. 6 September 2005. http://download. veritasmedicine. com/PDF/CR002392_CSR. pdf. ^ a b c "ANTI-INFECTIVE DRUGS ADVISORY COMMITTEE 62nd MEETING". U. S. Fda (FDA). 19 November 1996. http://fqresearch. org/pdf_files/62nd_fda_meeting. pdf. "One interesting case which isn't included on this slide for arthralgias became a 15 years old boy who received ofloxacin IV for an emergency appendectomy and had not grown over his 70 inches high throughout the last year. The 15th percentile for height to get a 15 year-old boy however is 66. 5 inches and also the expected rate of growth is approximately 2 " per yearThe third case is articular. This can be a 17-year-old patient who experienced arthropathy plus the drug was not suspected as well as the treatment was continued two following months. It contributes to destructive arthropathy on the knees and also the hip and prothesis was performed 36 months later. if an irreversible cartilaginous lesion can occur, it's probable which will lead to further problems later and we can't even anticipate what they are like(sic)" ^ a b Dolui SK, Das M, Hazra A (2007). "Ofloxacin-induced reversible arthropathy in the child". Journal of Postgraduate Medicine 53 (2): 1445. doi:10. 4103/0022-3859. 32220. PMID 17495385. ^ Division of Special Pathogen and Immunologic Drug Products Breakdown of Clinical Report on Studies Submitted in Response with a Pediatric Written Request ^ Chalumeau M, Tonnelier S, D'Athis P (June 2003). "Fluoroquinolone safety in pediatric patients: a prospective, multicenter, comparative cohort study in France". Pediatrics 111 (6 Pt 1): e7149. doi:10. 1542/peds. 111. 6. e714. PMID 12777590. http://pediatrics. aappublications. org/cgi/content/full/111/6/e714. Retrieved 2009-06-29. ^ "SYNOPSIS" (PDF). veritasmedicine. com. http://download. veritasmedicine. com/PDF/CR002392_CSR. pdf. ^ "SYNOPSIS" (PDF). veritasmedicine. com. http://download. veritasmedicine. com/PDF/CR002389_CSR. pdf. ^ "SYNOPSIS" (PDF). USA: veritasmedicine. com. http://download. veritasmedicine. com/PDF/CR002389_CSR. pdf. ^ Shepard CW, Soriano-Gabarro M, Zell ER (October 2002). "Antimicrobial Postexposure Prophylaxis for Anthrax: Adverse Events and Adherence". Emerging Infectious Diseases 8 (10): 112432. PMC 2730317. PMID 12396927. http://www. cdc. gov/ncidod/EID/vol8no10/02-0349. htm. Retrieved 2009-06-30. ^ "DOHMH ALERT #8:Fluoroquinolone-resistant gonorrhea, NYC". NY County Medical Society. 2004-04-30. http://www. nycms. org/article_view. php3view=947&part=1. Retrieved 2009-06-30. ^ Cdc and Prevention (CDC) (October 1995). "Fluoroquinolone resistance in Neisseria gonorrhoeae--Colorado and Washington, 1995". MMWR Morb. Mortal. Wkly. Rep. 44 (41): 7614. PMID 7565558. http://www. cdc. gov/mmwr/preview/mmwrhtml/00039305. htm. ^ Coban S, Ceydilek B, Ekiz F, Erden E, Soykan I (October 2005). "Levofloxacin-induced acute fulminant hepatic failure within a patient with chronic hepatitis B infection". Ann Pharmacother 39 (10): 173740. doi:10. 1345/aph. 1G111. PMID 16105873. ^ Cahill JB, Bailey EM, Chien S, Johnson GM (January 2005). "Levofloxacin secretion in breast milk: a claim report". Pharmacotherapy 25 (1): 1168. doi:10. 1592/phco. 25. 1. 116. 55616. PMID 15767227. ^ Nardiello S, Pizzella T, Ariviello R (March 2002). "[Risks of antibacterial agents in pregnancy"] (in Italian). Le Infezioni in Medicina 10 (1): 815. PMID 12700435. http://www. infezmed. it/VisualizzaUnArticolo. aspxAnno=2002&numero=1&ArticoloDaVisualizzare=Vol_10_1_2002_1. Retrieved 2009-06-30. ^ Loebstein R, Addis A, Ho E (June 1998). "Pregnancy Outcome Following Gestational Contact Fluoroquinolones: a Multicenter Prospective Controlled Study". Antimicrobial Agents and Chemotherapy 42 (6): 13369. PMC 105599. PMID 9624471. http://www. pubmedcentral. nih. gov/articlerender. fcgitool=pmcentrez&artid=105599. ^ Shin HC, Kim JC, Chung MK (September 2003). "Fetal and maternal tissue distribution with the new fluoroquinolone DW-116 in pregnant rats". Comp. Biochem. Physiol. C Toxicol. Pharmacol. 136 (1): 95102. doi:10. 1016/j. cca. 2003. 08. 004. PMID 14522602. ^ Dan M, Weidekamm E, Sagiv R, Portmann R, Zakut H (February 1993). "Penetration of fleroxacin into breast milk and pharmacokinetics in lactating women". Antimicrob. Agents Chemother. 37 (2): 2936. PMC 187655. PMID 8452360. http://www. pubmedcentral. nih. gov/articlerender. fcgitool=pmcentrez&artid=187655. ^ a b Noel GJ, Bradley JS, Kauffman RE (October 2007). "Comparative safety profile of levofloxacin in 2523 children with an importance on four specific musculoskeletal disorders". Pediatr. Infect. Dis. J. 26 (10): 87991. doi:10. 1097/INF. 0b013e3180cbd382. PMID 17901792. ^ a b c d e R. W. Johnson (20 December 1996). "Levaquin (Levofloxacin) NDA 20634". USA: U. S. Fda standards (FDA). http://www. accessdata. fda. gov/drugsatfda_docs/nda/96/020634_levaquin_toc. cfm. ^ a b - c "SYNOPSIS". USA. http://download. veritasmedicine. com/PDF/CR002392_CSR. pdf. Retrieved 29 January 2009. ^ "SYNOPSIS". USA. http://download. veritasmedicine. com/PDF/CR002389_CSR. pdf. Retrieved 29 January 2009. ^ Owens Rc, Jr; Ambrose, PG (July 2005). "Antimicrobial safety: give attention to fluoroquinolones". Clinical Infectious Diseases 41 Suppl 2: S14457. doi:10. 1086/428055. ISSN 1058-4838. PMID 15942881. ^ De Sarro A, De Sarro G (March 2001). "Adverse reactions to fluoroquinolones. a synopsis on mechanistic aspects" (PDF). Curr. Med. Chem. 8 (4): 37184. PMID 11172695. http://www. fqresearch. org/pdf_files/cmc. pdf. ^ http://www. fqresearch. org/text_documents/FDA_Medical_Bulletin_1996. doc ^ U S Fda standards (8 July 2008). "FDA Requests Boxed Warnings on Fluoroquinolone Antimicrobial Drugs". U. S. Food and Drug Administration (FDA). http://www. fda. gov/NewsEvents/Newsroom/PressAnnouncements/2008/ucm116919. htm. Retrieved 5 September 2009. ^ US Food (2008). "Fluoroquinolone Antimicrobial Drugs [ciprofloxacin (marketed as Cipro and generic ciprofloxacin), ciprofloxacin extended-release (marketed as Cipro XR and Proquin XR), gemifloxacin (marketed as Factive), levofloxacin (marketed as Levaquin), moxifloxacin (marketed as Avelox), norfloxacin (marketed as Noroxin), and ofloxacin (marketed as Floxin and generic ofloxacin)"]. USA. http://www. fda. gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm084316. htm. Retrieved 5 September 2009. [dead link] ^ a b US Federal drug administration. "Drugs at FDA: FDA Approved Drug Products". USA: U. S. Food (FDA). http://www. accessdata. fda. gov/scripts/cder/drugsatfda/index. cfmfuseaction=Search. Label_ApprovalHistory#apphist. Retrieved 5 September 2009. ^ a b - Rosenthal, Norman (November 2008). "Important Change in the LEVAQUIN (Ievofloxacin) Complete Prescribing Information -Addition of Boxed Warning and Medication Guide Regarding Tendinitis and Tendon Rupture". Ortho-McNeil Janssen Scientific Affairs, LLC. http://www. fqresearch. org/pdf_files/Levaquin_11_2008_ortho_mcneil_dear_dr_letter. pdf. Retrieved 2008-12-27. ^ a b - c Renata Albrecht (14 September 2004). "NDA 20-634/S-033, S-034, NDA 20-635/S-033, S-034". U. S. Fda (FDA). http://www. accessdata. fda. gov/drugsatfda_docs/appletter/2004/20634s033,034,20635s033,034ltr. pdf. ^ a b - Renata Albrecht (14 July 2004). "NDA 19-537/S-053, S-054, NDA 20-780/S-017, S-018". U. S. Food and Drug Administration (FDA). http://www. accessdata. fda. gov/drugsatfda_docs/appletter/2004/19537s053,054,20780s017,018ltr. pdf. Retrieved 5 September 2009. ^ a b - Renata Albrecht (18 December 2001). "NDA 20-634/S-015, S-021, S-022, NDA 20-635/S-012, S-019, S-020". U. S. Food (FDA). http://www. accessdata. fda. gov/drugsatfda_docs/appletter/2001/20634s15s21s22ltr. pdf. ^ Renata Albrecht (4 November 2004). "NDA 20-634/S-036, NDA 20-635/S-037". U. S. Fda (FDA). http://www. accessdata. fda. gov/drugsatfda_docs/appletter/2004/20635s037,20634s036ltr. pdf. ^ http://www. fqresearch. org/pub_med_levaquin/clostridum_difficicile_pub_med_levaquin. doc ^ a b - Petitjeans, F. ; Nadaud, J. ; Perez, JP. ; Debien, B. ; Olive, F. ; Villevieille, T. ; Pats, B. (December 2003). "A case of rhabdomyolysis with fatal outcome from a treatment with levofloxacin". Eur J Clin Pharmacol 59 (10): 77980. doi:10. 1007/s00228-003-0688-x. PMID 14576967. ^ a b - Hsiao, SH. ; Chang, CM. ; Tsao, CJ. ; Lee, YY. ; Hsu, MY. ; Wu, TJ. (January 2005). "Acute rhabdomyolysis regarding ofloxacin/levofloxacin therapy". Ann Pharmacother 39 (1): 1469. doi:10. 1345/aph. 1E285. PMID 15562138. ^ a b - Korzets, A. ; Gafter, U. ; Dicker, D. ; Herman, M. ; Ori, Y. (November 2006). "Levofloxacin and rhabdomyolysis inside a renal transplant patient". Nephrol Dial Transplant 21 (11): 33045. doi:10. 1093/ndt/gfl396. PMID 16968728. ^ Renata Albrecht (31 May 2007). "NDA 20-634/S-042, NDA 20-635/S-045, NDA 21-721/S-010". U. S. Food (FDA). http://www. accessdata. fda. gov/drugsatfda_docs/appletter/2007/020634s042,020635s045,021721s010ltr. pdf. ^ Renata Albrecht (19 June 2006). "NDA 19-537/S-062, NDA 20-780/S-023, NDA 19-847/S-037, NDA 19-857/S-042, NDA 21-473/S-016". U. S. Fda (FDA). http://www. accessdata. fda. gov/drugsatfda_docs/appletter/2006/019537s62,020780s23,019847s37,019857s42,021473s16LTR. pdf. Retrieved 5 September 2009. ^ a b Renata Albrecht (5 March 2004). "NDA 20-634/S-029, NDA 20-635/S-029". U. S. Fda (FDA). http://www. accessdata. fda. gov/drugsatfda_docs/appletter/2004/20634slr029,20635slr029ltr. pdf. ^ Cohen JS (December 2001). "Peripheral Neuropathy Related to Fluoroquinolones" (PDF). Ann Pharmacother 35 (12): 15407. doi:10. order differin online 1345/aph. 1Z429. PMID 11793615. http://fqvictims. org/fqvictims/News/neuropathy/Neuropathy. pdf. ^ Renata Albrecht (15 March 2004). "NDA 19-537/S-048, S-050, S-051 NDA 20-780/S-012, S-014, S-015". U. S. Food (FDA). http://www. accessdata. fda. gov/drugsatfda_docs/appletter/2004/19537slr048,050,051,20780slr012,014,015ltr. pdf. Retrieved September 2009. ^ Renata Albrecht (3 October 2008). "NDA 20-634/S-052, NDA 20-635/S-057, NDA 21-721/S-020". U. S. Fda standards (FDA). http://www. accessdata. fda. gov/drugsatfda_docs/appletter/2008/020634s052,%20020635s057,021721s020ltr%20. pdf. ^ Renata Albrecht (3 October 2008). "NDA 19-537/S-068, NDA 19-847/S-042, NDA 19-857/S-049, NDA 20-780/S-026, NDA 21-473/S-024". U. S. Food (FDA). http://www. accessdata. fda. gov/drugsatfda_docs/appletter/2008/019537s068,019847s042ltr. pdf. Retrieved 5 September 2009. ^ a b - Renata Albrecht (13 December 2007). "NDA 20-634/S-050, NDA 20-635/S-054, NDA 21-721/S-018". U. S. Fda standards (FDA). http://www. accessdata. fda. gov/drugsatfda_docs/appletter/2007/020634s050,%20020635s054,%20021721s018ltr. pdf. ^ Kushner, JM. ; Peckman, HJ. ; Snyder, CR. (October 2001). "Seizures related to fluoroquinolones". Ann Pharmacother 35 (10): 11948. doi:10. 1345/aph. 10359. PMID 11675843. ^ http://www. fqresearch. org/pub_med_levaquin/seizures_pub_med_levaquin. doc ^ Ozawa, TT. ; Valadez, T. (March 2002). "Clostridium difficile infection regarding levofloxacin treatment". Tenn Med 95 (3): 1135. PMID 11898264. ^ Gopal Rao, G. ; Mahankali Rao, CS. ; Starke, I. (March 2003). "Clostridium difficile-associated diarrhoea in patients with community-acquired lower respiratory infection receiving care with levofloxacin compared with beta-lactam-based therapy". J Antimicrob Chemother 51 (3): 697701. doi:10. 1093/jac/dkg115. PMID 12615873. ^ Muto CA, Pokrywka M, Shutt K (March 2005). "A large outbreak of Clostridium difficile-associated disease by having an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use". Infect Control Hosp Epidemiol 26 (3): 27380. doi:10. 1086/502539. PMID 15796280. http://www. journals. uchicago. edu/doi/pdf/10. 1086/502539. ^ Deshpande, A. ; Pant, C. ; Jain, A. ; Fraser, TG. ; Rolston, DD. (February 2008). "Do fluoroquinolones predispose patients to Clostridium difficile associated disease Overview of the evidence". Curr Med Res Opin 24 (2): 32933. doi:10. 1185/030079908X253735. PMID 18067688. ^ Cho, S. ; Breedlove, JJ. ; Gunning, ST. (January 2008). "Radiation recall reaction induced by levofloxacin". J Drugs Dermatol 7 (1): 647. PMID 18246700. ^ http://www. fqresearch. org/pub_med_levaquin/hypoglycemia_pib_med_levaquin. doc ^ http://www. fqresearch. org/pub_med_levaquin/kidney_damage_pub_med_levaquin. doc ^ Smythe, MA. ; Cappelletty, DM. (December 2000). "Anaphylactoid a reaction to levofloxacin". Pharmacotherapy 20 (12): 15203. doi:10. 1592/phco. 20. 19. 1520. 34868. PMID 11130225. ^ Takahama, H. ; Tsutsumi, Y. ; Kubota, Y. (September 2005). "Anaphylaxis on account of levofloxacin". Int J Dermatol 44 (9): 78990. doi:10. 1111/j. 1365-4632. 2004. 02325. x. PMID 16135155. ^ Gunduz, A. ; Turedi, S. ; Kalkan, A. ; Nuhoglu, I. (August 2006). "Levofloxacin induced myasthenia crisis". Emerg Med J 23 (8): 662. doi:10. 1136/emj. 2006. 038091. PMC 2564188. PMID 16858118. http://www. pubmedcentral. nih. gov/articlerender. fcgitool=pmcentrez&artid=2564188. ^ Mennecier, D. ; Thiolet, C. ; Bredin, C. ; Potier, V. ; Vergeau, B. ; Farret, O. (October 2001). "[Acute pancreatitis after treatment by levofloxacin and methylprednisolone]". Gastroenterol Clin Biol 25 (10): 9212. PMID 11852403. ^ Dominguez Jimenez, JL. ; Bernal Blanco, E. ; Marin Moreno, MA. ; Puente Gutierrez, JJ. (April 2009). "[Acute pancreatitis regarding levofloxacin"] (in Spanish). Gastroenterol Hepatol 32 (4): 3234. doi:10. 1016/j. gastrohep. 2008. 09. 027. PMID 19371975. http://www. elsevier. es/revistas/ctl_servlet_f=7064&ip=94. 7. 35. 23&articuloid=13136637&revistaid=14. ^ a b Fraunfelder, FW. ; Fraunfelder, FT. (September 2009). "Diplopia and fluoroquinolones". Ophthalmology 116 (9): 18147. doi:10. 1016/j. ophtha. 2009. 06. 027. PMID 19643481. ^ Grepinet, C. ; Guillocheau, E. ; Berteloot, A. ; Vachee, A. ; Herbin, O. ; Gautier, S. ; l'association des centres regionaux de pharmacovigilance (2008). "[Drug-induced fever during treatment with levofloxacin: a case-report]". Therapie 63 (4): 3413. PMID 19043827. ^ Lardizabal, DV. (February 2009). "Intracranial hypertension and levofloxacin: a claim report". Headache 49 (2): 3001. doi:10. 1111/j. 1526-4610. 2008. 01212. x. PMID 18647180. ^ Oh YR, Carr-Lopez SM, Probasco JM, Crawley PG (2003). "Levofloxacin-induced autoimmune hemolytic anemia". Ann Pharmacother 37 (78): 10103. doi:10. 1345/aph. 1C525. PMID 12841809. ^ Iannini, PB. (June 2007). "The safety profile of moxifloxacin along with fluoroquinolones in special patient populations". Curr Med Res Opin 23 (6): 140313. doi:10. 1185/030079907X188099. PMID 17559736. ^ Owens, RC. ; Ambrose, PG. (July 2005). "Antimicrobial safety: consentrate on fluoroquinolones". Clin Infect Dis 41 Suppl 2: S14457. doi:10. 1086/428055. PMID 15942881. ^ Saint, F. ; Gueguen, G. ; Biserte, J. ; Fontaine, C. ; Mazeman, E. (September 2000). "[Rupture with the patellar ligament one month after treatment with fluoroquinolone]". Rev Chir Orthop Reparatrice Appar Mot 86 (5): 4957. PMID 10970974. ^ Gangopadhyay, N. ; Daniell, M. ; Weih, L. ; Taylor, HR. (April 2000). "Fluoroquinolone and fortified antibiotics for the treatment of bacterial corneal ulcers". Br J Ophthalmol 84 (4): 37884. doi:10. 1136/bjo. 84. 4. 378. PMC 1723447. PMID 10729294. http://www. pubmedcentral. nih. gov/articlerender. fcgitool=pmcentrez&artid=1723447. ^ Walter, K. ; Tyler, ME. (August 2006). "Severe corneal toxicity after topical fluoroquinolone therapy: report of two cases". Cornea 25 (7): 8557. doi:10. 1097/01. ico. 0000224642. 43601. 14. PMID 17068466. ^ "Public Citizen Warns of Cipro Dangers". USA: Consumer affairs. 30 August 2006. http://www. consumeraffairs. com/news04/2006/08/pubcit_cipro. html. Retrieved 7 September 2009. ^ "FDA orders 'black box' label on some antibiotics". CNN. 2008-07-08. http://www. cnn. com/2008/HEALTH/07/08/antibiotics. risk/index. html. Retrieved 2008-07-08. ^ Hirano T, Yasuda S, Osaka Y (March 2008). "The inhibitory link between fluoroquinolones on L-carnitine transport in placental cell line BeWo". International Journal of Pharmaceutics 351 (12): 1138. doi:10. 1016/j. ijpharm. 2007. 09. 022. PMID 17977676. ^ Friedrich, LV. ; Dougherty, R. (December 2004). "Fatal hypoglycemia related to levofloxacin". Pharmacotherapy 24 (12): 180712. doi:10. 1592/phco. 24. 17. 1807. 52348. PMID 15585448. http://www. medscape. com/viewarticle/496197. ^ Melissa Hunt (January 2007). "Levofloxacin: dysglycemia and liver disorders" (PDF). Canadian adverse reaction newsletter (Canada: Health Canada Newsletter) 17 (1). http://www. hc-sc. gc. ca/dhp-mps/alt_formats/hpfb-dgpsa/pdf/medeff/carn-bcei_v17n1-eng. pdf. [dead link] ^ Levofloxacin works extremely well effectively like a positive control in thorough QT/QTc studies in healthy volunteersTaubel, Jorg; Naseem, A. , Harada, T. , Wang, D. , Arezina, R. , Lorch, U. and Camm, A. J. (2010) (November 2009). "Levofloxacin works extremely well effectively being a positive control in thorough QT/QTc studies in healthy volunteers". British Journal of Clinical Pharmacology 69 (4): 391400. doi:10. 1111/j. 1365-2125. 2009. 03595. x. PMC 2848412. PMID 20406223. http://www. pubmedcentral. nih. gov/articlerender. fcgitool=pmcentrez&artid=2848412. ^ "Showing drug card for Rimantadine (DB00478)". Canada. 23 June 2009. http://www. drugbank. ca/drugs/DB00478. ^ Drlica K, Zhao X (1 September 1997). "DNA gyrase, topoisomerase IV, and also the 4-quinolones". Microbiol Mol Biol Rev. 61 (3): 37792. PMC 232616. PMID 9293187. http://mmbr. asm. org/cgi/pmidlookupview=long&pmid=9293187. ^ Hussy P, Maass G, Tummler B, Grosse F, Schomburg U (June 1986). "Effect of 4-quinolones and novobiocin on calf thymus DNA polymerase alpha primase complex, topoisomerases I and II, and growth of mammalian lymphoblasts". Antimicrob. Agents Chemother. 29 (6): 10738. PMC 180502. PMID 3015015. http://aac. asm. org/cgi/reprint/29/6/1073. pdf. ^ "Mutagenicity of norfloxacin and AM-833 in bacteria and mammalian cells". Rev. Infect. 1 (jstor. org) 10: S148S149. 1988. JSTOR 4454399. ^ Forsgren A, Bredberg A, Pardee AB, Schlossman SF, Tedder TF (May 1987). "Effects of ciprofloxacin on eucaryotic pyrimidine nucleotide biosynthesis and cell growth". Antimicrobial Agents and Chemotherapy 31 (5): 7749. PMC 174831. PMID 3606077. http://www. pubmedcentral. nih. gov/articlerender. fcgitool=pmcentrez&artid=174831. ^ Gootz TD, Barrett JF, Sutcliffe JA (January 1990). "Inhibitory connection between quinolone antibacterial agents on eucaryotic topoisomerases and related test systems". Antimicrobial Agents and Chemotherapy 34 (1): 812. PMC 171510. PMID 2158274. http://www. pubmedcentral. nih. gov/articlerender. fcgitool=pmcentrez&artid=171510. ^ Lawrence JW, Darkin-Rattray S, Xie F, Neims AH, Rowe TC (February 1993). "4-Quinolones create a selective decrease of mitochondrial DNA from mouse L1210 leukemia cells". Journal of Cellular Biochemistry 51 (2): 16574. doi:10. 1002/jcb. 240510208. PMID 8440750. ^ Elsea SH, Osheroff N, Nitiss JL (5 July 1992). "Cytotoxicity of quinolones toward eukaryotic cells. Identification of topoisomerase II since the primary cellular target for your quinolone CP-115,953 in yeast" (PDF). The Journal of Biological Chemistry 267 (19): 131503. PMID 1320012. http://www. jbc. org/cgi/pmidlookupview=long&pmid=1320012. Retrieved 2009-06-03. ^ Suto MJ, Domagala JM, Roland GE, Mailloux GB, Cohen MA (December 1992). "Fluoroquinolones: relationships between structural variations, mammalian cell cytotoxicity, and antimicrobial activity". Journal of Medicinal Chemistry 35 (25): 474550. doi:10. 1021/jm00103a013. PMID 1469702. ^ Enzmann H, Wiemann C, Ahr HJ, Schluter G (April 1999). "Damage to mitochondrial DNA induced by the quinolone Bay y 3118 in embryonic turkey liver". Mutat. Res. 425 (2): 21324. doi:10. 1016/S0027-5107(99)00044-5. PMID 10216214. ^ Kashida Y, Sasaki YF, Ohsawa K (October 2002). "Mechanistic study on flumequine hepatocarcinogenicity working on DNA damage in mice". Toxicological Sciences : the state Journal in the Society of Toxicology 69 (2): 31721. doi:10. 1093/toxsci/69. 2. 317. PMID 12377980. http://toxsci. oxfordjournals. org/cgi/content/full/69/2/317. Retrieved 2009-06-30. ^ Thomas A, Tocher J, Edwards DI (May 1990). "Electrochemical characteristics of 5 quinolone drugs and influence on DNA damage and repair in Escherichia coli". The Journal of Antimicrobial Chemotherapy 25 (5): 73344. doi:10. 1093/jac/25. 5. 733. PMID 2165050. http://jac. oxfordjournals. org/cgi/pmidlookupview=long&pmid=2165050. Retrieved 2009-06-30. ^ "Fluoroquinolones and Quinolones". The American Academy of Optometry (British Chapter). http://www. academy. org. uk/pharmacy/fluoroq. htm. Retrieved 29 January 2009. ^ Yaseen A. Al-Soud; Najim A. Al-Masoudi (2003). "A new class of dihaloquinolones bearing N'-aldehydoglycosylhydrazides, mercapto-1,2,4-triazole, oxadiazoline and a-amino ester precursors: synthesis and antimicrobial activity". J. Braz. Chem. Soc 14 (5): 790796. doi:10. 1590/S0103-50532003000500014. http://www. scielo. br/scielo. phpscript=sci_arttext&pid=S0103-50532003000500014&lng=es&nrm=iso&tlng=es. "Nevertheless, some quinolones cause damage to the chromosome of eukaryotic cells. 21,22 These findings prompted us to optimize the substituent at C-3, by. . . " ^ Yaseen A. Al-Soud a and Najim A. Al-Masoudi (2003). "A New Class of Dihaloquinolones Bearing N'-Aldehydoglycosylhydrazides, Mercapto-1,2,4-triazole, Oxadiazoline and -Amino Ester Precursors: Synthesis and Antimicrobial Activity". J. Braz. Chem. Soc 14 (5): 790796. doi:10. 1590/S0103-50532003000500014. http://jbcs. sbq. org. br/jbcs/2003/v14_n5/13-048-02. pdf. "Although the present quinolones will not be accepted as potent inhibitors of eucaryotic topoisomerases, some effects on these and also other enzymes included in DNA replication are already observed" ^ Sissi C, Palumbo M (November 2003). "The quinolone family: from antibacterial to anticancer agents". Current Medicinal Chemistry 3 (6): 43950. doi:10. 2174/1568011033482279. PMID 14529452. "The present review specializes in the structural modifications liable for the transformation of an antibacterial into an anticancer agent. Indeed, a unique feature of drugs in accordance with the quinolone structure will be the astounding to different type II topoisomerase enzymes. Particularly, some congeners of the drug family display high activity not just against bacterial topoisomerases, and also against eukaryotic topoisomerases and are also toxic to cultured mammalian cells along with vivo tumor models" ^ Brouwers JR (1992). "Drug interactions with quinolone antibacterials". Drug Saf 7 (4): 26881. doi:10. 2165/00002018-199207040-00003. PMID 1524699. ^ Hilliard JJ, Krause HM, Bernstein JI (1995). "A comparison of active site binding of 4-quinolones and novel flavone gyrase inhibitors to DNA gyrase". Adv Exp Med Biol. 390: 5969. PMID 8718602. ^ Harder S, Fuhr U, Staib AH, Wolff T (November 1989). "Ciprofloxacin-caffeine: a drug interaction established using in vivo plus vitro investigations". Am. J. Med. 87 (5A): 89S91S. doi:10. 1016/0002-9343(89)90031-4. PMID 2589393. ^ Cooper JG, Harboe K, Frost SK, Skadberg O (April 2005). "Ciprofloxacin interacts with thyroid replacement therapy". BMJ 330 (7498): 1002. doi:10. 1136/bmj. 330. 7498. 1002. PMC 557149. PMID 15860826. http://www. bmj. com/cgi/content/full/330/7498/1002. ^ Domagala JM (April 1994). "Structure-activity and structure-side-effect relationships for that quinolone antibacterials". J. Antimicrob. Chemother. 33 (4): 685706. doi:10. 1093/jac/33. 4. 685. PMID 8056688. http://jac. oxfordjournals. org/cgi/reprint/33/4/685. ^ Janknegt R (November 1990). "Drug interactions with quinolones". J. Antimicrob. Chemother. 26 Suppl D: 729. PMID 2286594. ^ van der Linden PD, Sturkenboom MC, Herings RM, Leufkens HM, Rowlands S, Stricker BH (2003). "Increased chance of achilles tendon rupture with quinolone antibacterial use, specifically in elderly patients taking oral corticosteroids". Arch. Intern. Med. 163 (15): 18017. doi:10. 1001/archinte. 163. 15. 1801. PMID 12912715. http://archinte. ama-assn. org/cgi/content/full/163/15/1801. ^ Zacher, JL; Givone, DM (2004). "False-positive urine opiate screening related to fluoroquinolone use". Ann Pharmacother (38): 15251528. ^ University of Maryland Infirmary. "Levofloxacin". USA: University of Maryland. http://www. umm. edu/altmed/drugs/levofloxacin-075755. htm#U. S. %20Brand%20Names. ^ Takashi Shoda (23 October 2008). "UK Levofloxacin SPC and Underlying Patent Upheld by High Court Patent Court". USA: Daiichi Sankyo, Limited. http://www. daiichisankyo. com/news/yymmdd_nn. htmlb_newsrelease_n1_eng. detail%5Bid%5D=682. 3&b_newsrelease_n1_eng. year_selector%5Bid%5D=682. 3&b_newsrelease_n1_eng. category_selector%5Bid%5D=682. 3. [dead link] ^ Johnson & Johnson (2009). "Analysis of Sales by Business Segments" (PDF). Shareholder. p. 27. http://files. shareholder. com/downloads/JNJ/0x0x171267/057640f8-b2c0-4b0f-9f54-7a24a553c3ce/2007AR. pdf. ^ a b c "LEVAQUIN". USA: drugpatentwatch. com. http://www. drugpatentwatch. com/premium/preview/detail/index. phpsearchtype=alpha&category=Tradename&searchstring=LEVAQUIN. ^ Ed Lamb (1 May 2008). "Top 200 Drugs of 2007". USA: Pharmacy Times. http://www. pharmacytimes. com/issues/articles/2008-05_003. asp. [dead link] ^ "Levofloxacin". Tuberculosis (Edinb) 88 (2): 11921. March 2008. doi:10. 1016/S1472-9792(08)70013-1. PMID 18486047. ^ North DS, Fish DN, Redington JJ (1998). "Levofloxacin, a second-generation fluoroquinolone". Pharmacotherapy 18 (5): 91535. PMID 9758306. ^ Lemke, Thomas L. ; Williams, David A. (1 October 2007). Foye's Principles of Medicinal Chemistry (6 ed. ). USA: Lippincott Williams & Wilkins. ISBN 978-0781768795. http://books. google. com/id=NHQQBMM-qMEC&pg=PP1. ^ "Levaquin Information". USA: Medications. com. http://www. medications. com/drugs/levaquin. ^ King DE, Malone R, Lilley SH (May 2000). "New classification boost within the quinolone antibiotics". American Family Physician 61 (9): 27418. PMID 10821154. http://www. aafp. org/afp/20000501/2741. html. Retrieved 2009-06-30. ^ Davis R, Bryson HM (April 1994). "Levofloxacin. An assessment of its antibacterial activity, pharmacokinetics and therapeutic efficacy". Drugs 47 (4): 677700. doi:10. 2165/00003495-199447040-00008. PMID 7516863. ^ "STATISTICAL REVIEW AND EVALUATION" (PDF). USA: U. S. Food and Drug Administration (FDA). 21 November 1996. http://www. accessdata. fda. gov/drugsatfda_docs/nda/96/020634-4. pdf. ^ 2009 shareholders meeting; time stamped at 1 hour 42 minutes ^ [1][dead link] ^ Ed Lamb (1 May 2008). "Top 200 Prescription Drugs of 2007". Pharmacy Times. http://www. pharmacytimes. com/issues/articles/2008-05_003. asp. Retrieved 21 July 2009. [dead link] ^ Cravit, Cravit Ophthalmic, Elequine, Floxel, Iquix, Leroxacin, Lesacin, Levaquin, Levokacin, Levox, Levoxacin, Mosardal, Nofaxin, Quixin, Reskuin, Tavanic, Volequin http://www. drugbank. ca/drugs/DB01137 ^ Cravox, Floxlevo, Levoxacine, Levoxetina, Nislev, Oftaquix, Prixar, Reskuin, Tavanic source: http://www. umm. edu/altmed/drugs/levofloxacin-075755. htm#International%20Brand%20Names ^ a b "Novopharm Limited". USA. 3 November 2009. http://investing. businessweek. com/research/stocks/private/snapshot. aspprivcapId=4240255. ^ JOHNSON & JOHNSON (28 March 2004). "UNITED STATES SECURITIES AND EXCHANGE COMMISSION". USA: shareholder. com. pp. 2829. http://apps. shareholder. com/sec/viewerContent. aspxcompanyid=JNJ&docid=2940855. ^ "NDA 20-634/S-054, NDA 20-635/S-059, NDA 21-721/S-022". U. S. Federal drug administration (FDA). 12 March 2009. http://www. accessdata. fda. gov/drugsatfda_docs/appletter/2009/020634s054,020635s059,021721s022ltr. pdf. ^ Ozlem Belen (27 March 2009). "NDA 20-634/S-053, NDA 20-635/S-058, NDA 21-721/S-021". U. S. Fda (FDA). http://www. accessdata. fda. gov/drugsatfda_docs/appletter/2009/020634s053,020635s058,021721s021lt. pdf. ^ Ortho-McNeil-Janssen Pharmaceuticals, Inc. (October 2008). "FDA-Approved Medication Guide". U. S. Fda (FDA). http://www. accessdata. fda. gov/drugsatfda_docs/label/2009/020634s053,020635s058,%20021721s021lbl. pdf. ^ Levaquin (Levofloxacin) ^ Renata Albrecht (3 October 2008). "NDA 19-735/S-059". U. S. Fda standards (FDA). http://www. accessdata. fda. gov/drugsatfda_docs/appletter/2008/019735s059ltr. pdf. ^ Bailey RR, Natale R, Linton AL (October 1972). "Nalidixic acid arthralgia". Can Med Assoc J 107 (7): 604 passim. PMC 1940945. PMID 4541768. http://www. pubmedcentral. nih. gov/articlerender. fcgitool=pmcentrez&artid=1940945. ^ Bailey RR, Kirk JA, Peddie BA (July 1983). "Norfloxacin-induced rheumatic disease". N Z Med J 96 (736): 590. PMID 6223241. ^ Szarfman A, Chen M, Blum MD (January 1995). "More on fluoroquinolone antibiotics and tendon rupture" (letter). N Engl J Med 332 (3): 193. doi:10. 1056/NEJM199501193320319. PMID 7800023. ^ a b "Petition to want a stern warning on All Fluoroquinolone Antibiotics (HRG Publication #1399)". Public Citizen. August 1, 1996. http://www. citizen. org/publications/release. cfmID=6595. Retrieved on December 27, 2008. ^ "Reports of adverse events with fluoroquinolones". FDA Medical Bulletin 26 (3). October 1996. http://www. fda. gov/medbull/oct96/adverse. html. [dead link] Retrieved on December 27, 2008. alternate link: http://www. fqresearch. org/text_documents/FDA_Medical_Bulletin_1996. doc ^ a b - "Madigan, Public Citizen, petition FDA for "black box" warning regarding potential adverse effects of certain popular antibiotics" (News release). Office from the Illinois Attorney General. August 29, 2006. http://www. illinoisattorneygeneral. gov/pressroom/2006_08/20060829. html. Retrieved 2008-12-27. Full text from the 2005 petition and FDA response which is available from the Fluoroquinolone Toxicity Research Foundation, a U. S. consumer advocacy group. ^ a b - "Public Citizen Petitions the FDA to add a Black Box Warning on Fluoroquinolone Antibiotics (HRG Publication #1781)". Public Citizen. August 29, 2006. http://www. citizen. org/publications/release. cfmID=7453. Retrieved 2008-12-27. ^ "Public Citizen v. Food (FDA) (Fluoroquinolone)". Public Citizen. January 3, 2008. http://www. citizen. org/litigation/forms/cases/CaseDetails. cfmcID=444. Retrieved 2008-12-27. ^ Ravn, Karen (August 18, 2008). "Behind the FDA's 'black box' warnings". La Times. http://articles. latimes. com/2008/aug/18/health/he-closer18. Retrieved 2008-12-27. ^ "FDA Requests Boxed Warnings on Fluoroquinolone Antimicrobial Drugs" (Blog post). U. S. Food. 2008-07-08. http://www. fda. gov/bbs/topics/NEWS/2008/NEW01858. html. Retrieved 2008-10-11. ^ FDA Requests Boxed Warnings on Fluoroquinolone Antimicrobial Drugs ^ MacCarthy, Paul (October 22, 2008). "Important Improvement in the Avelox (moxifloxacin hydrochloride) and Cipro (ciprofloxacin) Complete Prescribing Information Addition of Boxed Warning and Medication Guide Regarding Tendinitis and Tendon Rupture". Bayer HealthCare Pharmaceuticals. http://www. cipro. com/html/pdf/dhpl. pdf. Retrieved 2008-12-27. ^ M Jacobs, Worldwide Breakdown of Antimicrobial Resistance. International Symposium on Antimicrobial Agents and Resistance 2005. ^ Robicsek A, Jacoby GA, Hooper DC (October 2006). "The worldwide emergence of plasmid-mediated quinolone resistance". The Lancet Infectious Diseases 6 (10): 62940. doi:10. 1016/S1473-3099(06)70599-0. PMID 17008172. ^ Jim Hoover, for Bayer Corporation, Alaska Pharmacy and Therapeutics Committee March 19, 2004 ^ Froom J, Culpepper L, Jacobs M (July 1997). "Antimicrobials for acute otitis media An assessment on the International Primary Care Network". BMJ (Clinical Research Ed. ) 315 (7100): 98102. PMC 2127061. PMID 9240050. http://www buy indometacin. pubmedcentral. nih. gov/articlerender. fcgitool=pmcentrez&artid=2127061. ^ Linder JA, Huang ES, Steinman MA, Gonzales R, Stafford RS (March 2005). "Fluoroquinolone prescribing in the usa: 1995 to 2002". The American Journal of drugs 118 (3): 25968. doi:10. 1016/j. amjmed. 2004. 09. 015. PMID 15745724. ^ K08 HS14563 and HS11313 ^ Public Citizen; Michael T. Kickpatrick (3 January 2008). "In America District Court For your District Of Columbia" (PDF). USA: Carey & Danis, LLC. Archived on the original on 2008. http://www. fqresearch. org/fda_suit. htm. ^ Lisa Madigan (18 May 2005). "Office Of The Attorney General State Of Illinois, CITIZEN PETITION". U. S. Federal drug administration (FDA). Archived from the original on 2005. http://www. fqresearch. org/pdf_files/fda_response. pdf. ^ Jane A. Axelrad (16 November 2005). "Re: Docket No. 2005P-0205". U. S. Food and Drug Administration (FDA). http://www. fqresearch. org/pdf_files/illinois. pdf. ^ Michael A. Friedman, M. D. (9 June 1998). "Petition on the Fda standards to right away stop the distribution of dangerous, misleading prescription drug information towards the public. (HRG Publication #1442)". USA: Public Citizen. Archived in the original on 2007. http://fqresearch. org/HRG_Publication_1442. htm. ^ Public Citizen. "Patently Offensive: Congress Set to boost Monopoly Patents for Cipro as well as other Drugs". USA: Citizen. org. http://www. citizen. org/print_article. cfmID=6435. [dead link] ^ "SYNOPSIS" (PDF). USA: Veritas Medicine. 30 June 2004. http://download. veritasmedicine. com/PDF/CR002389_CSR. pdf. Retrieved 13 August 2009. ^ Susan Todd (January 15, 2010). "Johnson&Johnson accused of paying kickbacks to pharmacy chain Omnicare". The Star-Ledger. http://www. nj. com/business/index. ssf/2010/01/johnsonjohnson_accused_of_payi. html. ^ Natasha Singer (January 15, 2010). "Johnson & Johnson Accused of Drug Kickbacks". The New York Times. http://www. nytimes. com/2010/01/16/business/16drug. html. ^ [2][dead link] ^ "Levaquin MDL 08-MD-1943". USA: US District Court District of Minnesota. http://www. mnd. uscourts. gov/MDL-Levaquin/index. shtml. Retrieved 7 September 2009. ^ Charles Toutant (6 July 2009). "Litigation Over Johnson & Johnson Antibiotic Levaquin Designated N. J. Mass Tort". New Jersey Law Journal. http://www. law. com/jsp/article. jspid=1202431984309. ^ Reed Abelson; Natasha Singer (October 14, 2011). "Johnson & Johnson Wins Suit Over Antibiotic's Side Effects". The modern York Times. http://www. nytimes. com/2011/10/15/business/johnson-johnson-wins-suit-over-levaquins-side-effects. html. ^ Carey and Danis LLC (3 September 2009). "Carey and Danis LLC Announces Four Lawsuits up against the Makers of Levaquin". Reuters. http://www. reuters. com/article/pressRelease/idUS199242+03-Sep-2009+BW20090903. ^ The Southeast Texas Record. Apr. 17, 2010 S. E. Texas' Legal Journal Class action lawsuit alleges antibiotic causes tendon damage 4/15/2010 8:21 AM By Michelle Massey, East Texas Bureau http://www. setexasrecord. com/news/226050-class-action-alleges-antibiotic-causes-tendon-damage ^ The us District Court District Of Minnesota (12 May 2009). "DEFENDANT JOHNSON & JOHNSON'S ANSWER TO PLAINTIFF'S COMPLAINT" (PDF). USA. http://www. fqresearch. org/pdf_files/232-1. pdf. [dead link] ^ $1,800,000. 00 Verdict Obtained for Man Injured through the Drug Levaquin. Source: http://www. seedol. com/20116773-mikal-watts-obtains-first-levaquin-verdict-in-the-nation. html ^ "Anthrax Scare Leaves Trail of Cipro Victims - Class Actions filed in 2 States". USA: Sheller Ludwig & Sheller. 17 October 2003. http://www. sheller. com/NewsDetails. aspNewsID=72. Retrieved 9 September 2009. [dead link] ^ "LEGAL BRIEF of Postal Employees Cases (EEOC, MSPB, District Courts)". USA: Postal Reporter. http://www. lunewsviews. com/legal_briefs_archives. htm#cipro. Retrieved 9 September 2009. ^ Charles P. Goodell, Jr. "Profile". USA: Goodell, DeVries, Leech & Dann, LLP. http://www. gdldlaw. com/content/bio_goodell. htm. Retrieved 9 September 2009. . Current Mood: predatory (Comment on this)
1:53 am	Amoxil (amoxicillin) drug information: user reviews, drug unwanted effects, interactions and dosage Amoxicillin is stable within the presence of gastric acid and is particularly rapidly absorbed after oral administration. The effects of food on the absorption of amoxicillin from the tablets and suspension of AMOXIL (amoxicillin) has been partially investigated. The 400-mg and 875-mg formulations have already been studied as long as administered on the start of a light meal. However, food effect numerous studies have shown not been performed with all the 200-mg and 500-mg formulations. Amoxicillin diffuses readily into most body tissues and fluids, with the exception of brain and spinal fluid, except when meninges are inflamed. The half-life of amoxicillin is 61. 3 minutes. Most with the amoxicillin is excreted unchanged within the urine; its excretion may be delayed by concurrent administration of probenecid. In blood serum, amoxicillin is approximately 20% protein-bound. Orally administered doses of 250-mg and 500-mg amoxicillin capsules result in average peak blood levels 1 or 2 hours after administration from the range of 3. 5 mcg/mL to 5. 0 mcg/mL and 5. 5 mcg/mL to 7. 5 mcg/mL, respectively. Mean amoxicillin pharmacokinetic parameters from an open, two-part, single-dose crossover bioequivalence study in 27 adults comparing 875 mg of AMOXIL with 875 mg of AUGMENTIN (amoxicillin/clavulanate potassium) demonstrated that the 875-mg tablet of AMOXIL (amoxicillin) produces an AUC0-∞ of 35. 4 8. 1 mcg•hr/mL as well as a Cmax of 13. 8 4. 1 mcg/mL. Dosing was at the oncoming of the light meal following an overnight fast. Orally administered doses of amoxicillin suspension, 125 mg/5 mL and 250 mg/5 mL, lead to average peak blood levels 1 to 2 hours after administration in the plethora of 1. 5 mcg/mL to 3. 0 mcg/mL and three. 5 mcg/mL to. 0 mcg/mL, respectively. Oral administration of single doses of 400-mg chewable tablets and 400 mg/5 mL suspension of AMOXIL (amoxicillin) to 24 adult volunteers yielded comparable pharmacokinetic data: Dose* AUC0-∞ (mcg• hr/mL) Cmax (mcg/mL) Amoxicillin amoxicillin (S. D. ) amoxicillin (S. D. ) 400 mg (5 mL of suspension) 17. 1 (3. 1) 5. 92 (1. 62) 400 mg (1 chewable tablet) 17. 9 (2. 4) 5. 18 (1. 64) * Administered at the start of a lightweight meal. Mean values of 24 normal volunteers. Peak concentrations occurred approximately An hour following dose. Detectable serum levels are observed approximately 8 hours after an orally administered dose of amoxicillin. Carrying out a 1-gram dose and making use of its own skin window process to determine quantity of a antibiotic, it had been noted that therapeutic levels put together from the interstitial fluid. Approximately 60% of your orally administered dose of amoxicillin is excreted inside urine within 5 to 9 hours. Microbiology Amoxicillin resembles ampicillin in its bactericidal action against susceptible organisms throughout the stage of active multiplication. It acts over the inhibition of biosynthesis of cell wall mucopeptide. Amoxicillin can be active against most strains with the following microorganisms, in the vitro along with clinical infections as described inside INDICATIONS AND USAGE section. Aerobic Gram-Positive Microorganisms Enterococcus faecalis Staphylococcus spp. * (β-lactamase-negative strains only) Streptococcus pneumoniae Streptococcus spp. (α- and β-hemolytic strains only) * Staphylococci that happen to be subject to amoxicillin but resistant to methicillin/oxacillin should be thought about as resistance against amoxicillin. Aerobic Gram-Negative Microorganisms Escherichia coli (β-lactamase-negative strains only) Haemophilus influenzae (β-lactamase-negative strains only) Neisseria gonorrhoeae (β-lactamase-negative strains only) Proteus mirabilis (β-lactamase-negative strains only) Helicobacter Helicobacter pylori Susceptibility Tests Dilution Techniques Quantitative methods are widely used to determine antimicrobial minimum inhibitory concentrations (MICs). These MICs provide estimates from the susceptibility of bacteria to antimicrobial compounds. The MICs really should be determined having a standardized procedure. Standardized procedures depend on a dilution method1 (broth or agar) or equivalent with standardized inoculum concentrations and standardized concentrations of ampicillin powder buy keflex online. Ampicillin is oftentimes used to predict susceptibility of S. pneumoniae to amoxicillin; however, some intermediate strains have been shown to be prone to amoxicillin. Therefore, S. pneumoniae susceptibility should be tested using amoxicillin powder. The MIC values needs to be interpreted good following criteria: For Gram-Positive Aerobes Enterococcus MIC (mcg/mL) Interpretation ≤ 8 Susceptible(S) ≥ 16 Resistant(R) Staphylococcusa MIC (mcg/mL) Interpretation ≤ 0. 25 Susceptible(S) ≥ 0. 5 Resistant(R) Streptococcus (except S. pneumoniae) MIC (mcg/mL) Interpretation ≤0. 25 Susceptible(S) 0. 5 to 4 Intermediate(I) ≥ 8 Resistant(R) S. pneumoniaeb from non-meningitis sources. (Amoxicillin powder needs to be employed to determine susceptibility. ) MIC (mcg/mL) Interpretation ≤2 Susceptible(S) 4 Intermediate(I) ≥ 8 Resistant(R) NOTE: These interpretive criteria use the recommended doses for respiratory system infections. For Gram-Negative Aerobes Enterobacteriaceae MIC (mcg/mL) Interpretation ≤8 Susceptible(S) 16 Intermediate(I) ≥ 32 Resistant(R) H. influenzaec MIC (mcg/mL) Interpretation ≤ 1 Susceptible(S) 2 Intermediate(I) ≥4 Resistant(R) a. Staphylococci that are susceptible to amoxicillin but immune to methicillin/oxacillin should be considered as resistant against amoxicillin. b. These interpretive standards can be applied only to broth microdilution susceptibility tests using cation-adjusted Mueller-Hinton broth with 2-5% lysed horse blood. c. These interpretive standards are applicable and then broth microdilution test with H. influenzae using Haemophilus Test Medium (HTM). 1 A report of "Susceptible" shows that the pathogen probably will be inhibited when the antimicrobial compound from the blood reaches the concentrations usually achievable. A study of "Intermediate" shows that the result should be thought about equivocal, and, if the microorganism is just not fully subject to alternative, clinically feasible drugs, test really should be repeated. This category implies possible clinical applicability in body sites in which the drug is physiologically concentrated or even in situations where high dosage of drug may be used. This category also comes with a buffer zone, which prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A study of "Resistant" shows that the pathogen is not likely to become inhibited when the antimicrobial compound in the blood reaches the concentrations usually achievable; other therapy ought to be selected. Standardized susceptibility test procedures require the utilization of laboratory control microorganisms to manage the technical issues with the laboratory procedures. Standard ampicillin powder ought to provide the subsequent MIC values: Microorganism MIC Range (mcg/mL) E. buy quinine online coli ATCC 25922 2 to eight E. faecalis ATCC 29212 0. 5 to two H. influenzae ATCC 49247d 2 to 8 S. aureus ATCC 29213 0. 25 one Using amoxicillin to determine susceptibility: Microorganism MIC Range (mcg/mL) S. pneumoniae ATCC 49619e 0. 03 to 0. 12 d. This qc range can be applied to only H. influenzae ATCC 49247 tested with a broth microdilution procedure using HTM. 1 e. This quality control range does apply only to S. pneumoniae ATCC 49619 tested from the broth microdilution procedure using cation-adjusted Mueller-Hinton broth with 2-5% lysed horse blood. Diffusion Techniques Quantitative methods which need measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. One standardized procedure2 requires the usage of standardized inoculum concentrations. This process uses paper disks impregnated with 10 mcg ampicillin to find out the susceptibility of microorganisms, except S. pneumoniae, to amoxicillin. Interpretation involves correlation in the diameter obtained inside disk test while using MIC for ampicillin. Reports through the laboratory providing outcomes of the typical single-disk susceptibility test having a 10-mcg ampicillin disk must be interpreted in accordance with the following criteria: For Gram-Positive Aerobes Enterococcus Zone Diameter (mm) Interpretation ≥ 17 Susceptible(S) ≤ 16 Resistant(R) Staphylococcusf Zone Diameter (mm) Interpretation ≥ 29 Susceptible(S) ≤ 28 Resistant(R) α-hemolytic streptococci Zone Diameter (mm) Interpretation ≥26 Susceptible(S) 19 to 25 Intermediate(I) ≤ 18 Resistant(R) NOTE: For streptococci (other than β-hemolytic streptococci and S. pneumoniae), an ampicillin MIC should be determined. S. pneumoniae S. pneumoniae should be tested utilizing a 1-mcg oxacillin disk. Isolates with oxacillin zone sizes of ≥20 mm are inclined to amoxicillin. An amoxicillin MIC should be determined on isolates of S. pneumoniae with oxacillin zone sizes of 19 mm. For Gram-Negative Aerobes Enterobacteriaceae Zone Diameter (mm) Interpretation ≥17 Susceptible(S) 14 to 16 Intermediate(I) ≤ 13 Resistant(R) H. influenzaeg Zone Diameter (mm) Interpretation ≥ 22 Susceptible(S) 19 to 21 Intermediate(I) ≤ 18 Resistant(R) f. Staphylococci which can be prone to amoxicillin but immune to methicillin/oxacillin should be thought about as immune to amoxicillin. g. These interpretive standards are applicable just to disk diffusion susceptibility tests with H. influenzae using Haemophilus Test Medium (HTM). 2 Interpretation must be mentionened above previously above for results using dilution techniques. As with standard dilution techniques, disk diffusion susceptibility test procedures need the use of laboratory control microorganisms. The 10-mcg ampicillin disk must provide the following zone diameters within these laboratory test quality control strains: Microorganism Zone Diameter (mm) E. coli ATCC 25922 16 to 22 H. influenzae ATCC 49247h 13 to 21 S. aureus ATCC 25923 27 to 35 Using 1-mcg oxacillin disk: Microorganism Zone Diameter (mm) S. pneumoniae ATCC 49619I 8-12 h. This quality control range is relevant just to H. influenzae ATCC 49247 tested by way of a disk diffusion procedure using HTM. 2 i. This qc range is applicable to simply S. pneumoniae ATCC 49619 tested using a disk diffusion procedure using Mueller-Hinton agar supplemented with 5% sheep blood and incubated in 5% CO2. Susceptibility Testing for Helicobacter pylori In vitro susceptibility testing methods and diagnostic products available today for determining minimum inhibitory concentrations (MICs) and zone sizes have not been standardized, validated, or approved for testing H. pylori microorganisms. Culture and susceptibility testing really should be obtained in patients who fail triple therapy. If clarithromycin resistance is located, a non-clarithromycin-containing regimen really should be used. Clinical Studies H. pylori Eradication to relieve the chance of Duodenal Ulcer Recurrence: Randomized, double-blind studies performed in the states in patients with H. pylori and duodenal ulcer disease (looked as an active ulcer or good reputation for an ulcer within 1 year) evaluated the efficacy of lansoprazole in conjunction with amoxicillin capsules and clarithromycin tablets as triple 14-day therapy, or in combination with amoxicillin capsules as dual 14-day therapy, to the eradication of H. pylori. Based on the results of those studies, the security and efficacy of two different eradication regimens were established: Triple Therapy: Amoxicillin 1 gram twice daily/clarithromycin 500 mg twice daily/lansoprazole 30 mg two times a day. Dual Therapy: Amoxicillin 1 gram 3 times daily/lansoprazole 30 mg three times daily. All treatments were for 2 weeks. H. pylori eradication was looked as 2 negative tests (culture and histology) at Four to six weeks pursuing the end of treatment. Triple therapy was demonstrated that they are more potent than all possible dual therapy combinations. Dual therapy was demonstrated that they are better than both monotherapies. Eradication of H. pylori may limit the risk of duodenal ulcer recurrence. H. pylori Eradication Rates - Triple Therapy (amoxicillin/clarithromycin/lansoprazole) Percent of Patients Cured [95% Confidence Interval] (Number of Patients) Study Triple Therapy Triple Therapy Evaluable Analysis* Intent-to-Treat Analysis Study 1 92 86 [80. 0 - 97. 7] [73. 3 - 93. 5] (n = 48) (n = 55) Study 2 86 83 [75. 7 - 93. 6] [72. 0 - 90. 8] (n = 66) (n = 70) * This analysis was based on evaluable patients with confirmed duodenal ulcer (active or within Twelve months) and H. pylori infection at baseline understood to be at least 2 of three positive endoscopic tests from CLOtest, (Delta West Ltd. , Bentley, Australia), histology, and/or culture. Patients were contained in the analysis if they completed the study. Additionally, if patients dropped out of the study because of an adverse event associated with the investigation drug, we were holding contained in the analysis as failures of therapy. Patients were as part of the analysis when they had documented H. pylori infection at baseline as defined above along a confirmed duodenal ulcer (active or within 1 year). All dropouts were included as failures of therapy. (p<0. 05) versus lansoprazole/amoxicillin and lansoprazole/clarithromycin dual therapy. (p<0. 05) versus clarithromycin/amoxicillin dual therapy. H. pylori Eradication Rates - Dual Therapy (amoxicillin/lansoprazole) Percent of Patients Cured [95% Confidence Interval] (Number of Patients) Study Dual Therapy Dual Therapy Evaluable Analysis* Intent-to-Treat Analysis Study 1 77 70 [62. 5 - 87. 2] [56. 8 - 81. 2] (n = 51) (n = 60) Study 2 66 61 [51. 9 - 77. 5] [48. 5 - 72. 9] (n = 58) (n = 67) * This analysis scaled like evaluable patients with confirmed duodenal ulcer (active or within A year) and H. pylori infection at baseline thought of as a minimum of 2 of three positive endoscopic tests from CLOtest, histology, and/or culture. Patients were included in the analysis as long as they completed case study. Additionally, if patients dropped from the study due to a poor event relevant to the study drug, they were in the analysis as failures of therapy. Patients were included in the analysis as long as they had documented H. pylori infection at baseline as defined above and had a confirmed duodenal ulcer (active or within One year). All dropouts were included as failures of therapy. (p<0. 05) versus lansoprazole alone. (p<0. 05) versus lansoprazole alone or amoxicillin alone. References 1. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically - Fourth Edition; Approved Standard NCCLS Document M7-A4, Vol. 17, No. 2. NCCLS, Wayne, PA, January 1997. 2. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Disk Susceptibility Tests - Sixth Edition; Approved Standard NCCLS Document M2-A6, Vol. 17, No. 1. NCCLS, Wayne, PA, January 1997. Last reviewed on RxList: 10/25/2010 This monograph has become modified to feature the generic and name brand most often. . Current Mood: sad (Comment on this)